Ippolito Marica Rosaria, Zerbib Johanna, Eliezer Yonatan, Reuveni Eli, Viganò Sonia, De Feudis Giuseppina, Shulman Eldad D, Savir Kadmon Anouk, Slutsky Rachel, Chang Tiangen, Campagnolo Emma M, Taglietti Silvia, Scorzoni Simone, Gianotti Sara, Martin Sara, Muenzner Julia, Mülleder Michael, Rozenblum Nir, Rubolino Carmela, Ben-Yishay Tal, Laue Kathrin, Cohen-Sharir Yael, Vigorito Ilaria, Nicassio Francesco, Ruppin Eytan, Ralser Markus, Vazquez Francisca, Santaguida Stefano, Ben-David Uri
Department of Experimental Oncology at IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cancer Discov. 2024 Dec 2;14(12):2532-2553. doi: 10.1158/2159-8290.CD-23-0309.
Aneuploidy results in a stoichiometric imbalance of protein complexes that jeopardizes cellular fitness. Aneuploid cells thus need to compensate for the imbalanced DNA levels by regulating their RNA and protein levels, but the underlying molecular mechanisms remain unknown. In this study, we dissected multiple diploid versus aneuploid cell models. We found that aneuploid cells cope with transcriptional burden by increasing several RNA degradation pathways, and are consequently more sensitive to the perturbation of RNA degradation. At the protein level, aneuploid cells mitigate proteotoxic stress by reducing protein translation and increasing protein degradation, rendering them more sensitive to proteasome inhibition. These findings were recapitulated across hundreds of human cancer cell lines and primary tumors, and aneuploidy levels were significantly associated with the response of patients with multiple myeloma to proteasome inhibitors. Aneuploid cells are therefore preferentially dependent on several key nodes along the gene expression process, creating clinically actionable vulnerabilities in aneuploid cells. Significance: Aneuploidy is a hallmark of cancer that is associated with poor prognosis and worse drug response. We reveal that cells with extra chromosomes compensate for their imbalanced DNA content by altering their RNA and protein metabolism, rendering them more sensitive to perturbation of RNA and protein degradation. See related commentary by Bakhoum, p. 2315.
非整倍体导致蛋白质复合物的化学计量失衡,危及细胞适应性。因此,非整倍体细胞需要通过调节其RNA和蛋白质水平来补偿失衡的DNA水平,但其潜在的分子机制仍然未知。在本研究中,我们剖析了多个二倍体与非整倍体细胞模型。我们发现,非整倍体细胞通过增加几种RNA降解途径来应对转录负担,因此对RNA降解的扰动更敏感。在蛋白质水平上,非整倍体细胞通过减少蛋白质翻译和增加蛋白质降解来减轻蛋白毒性应激,使其对蛋白酶体抑制更敏感。这些发现在数百个人类癌细胞系和原发性肿瘤中得到了验证,并且非整倍体水平与多发性骨髓瘤患者对蛋白酶体抑制剂的反应显著相关。因此,非整倍体细胞在基因表达过程中优先依赖于几个关键节点,从而在非整倍体细胞中产生临床上可利用的脆弱性。意义:非整倍体是癌症的一个标志,与预后不良和较差的药物反应相关。我们发现,具有额外染色体的细胞通过改变其RNA和蛋白质代谢来补偿其失衡的DNA含量,使其对RNA和蛋白质降解的扰动更敏感。见Bakhoum的相关评论,第2315页。